Omar Farooq Abdul-Rasheed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Omar Farooq Abdul-Rasheed has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Zaid Mahdi Jaber Al-Obaidi
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Alkafeel, Najaf, Iraq
4 shared publications Monther F Mahdi
Department of Pharmaceutical Chemistry, Ashur University College, Baghdad, Baghdad, Iraq
3 shared publications- Anmar R. Raheem
Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Kadhmyia, Baghdad, Iraq
2 shared publications Ayad M R Raauf
Department of Pharmaceutical Chemistry, University of Mustansiriyah, Baghdad, Baghdad, Iraq
2 shared publicationsEmad A. Abdulghani
From the Department of Pharmacy (Abdulamir), Al Yarmouk University College, from the Department of Chemistry and Biochemistry (Abdul-Rasheed), College of Medicine, Al-Nahrain University; and from the Mental Health (Abdulghani), Ministry of Health, Baghdad, Iraq
2 shared publications- Haidar A. Abdulamir
Ollege of Pharmacy-Al-Maaql University, Basra-Iraq
2 shared publications
Latest Publications
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2230-2238
The investigation of new mutations in telomerase reverse transcriptase promoter region in association with bladder cancer
Telomerase reverse transcriptase (TERT) is frequently reactivated in Urothelial Bladder Cancer (UBC) due to changes in its promoter region, rendering it a vital target for cancer-specific genetic modifications. The present work was aimed to investigate the TERT promoter region to explore the mutations that may affect the incidence and the pathogenesis of Urothelial Bladder Cancer in a study included 59 patients subjected to either transurethral bladder resection or radical cystectomy from which serum and tissue samples were obtained and the DNA extraction was performed with the use of purification Promega kit and the amplified DNA samples were sequenced by Sanger sequencing using an automated DNA sequencer to determine TERT gene promoter mutations. The results of the study showed that 47 patients out of 59 showed a mutation at the position -129 (1295233), 44 of them with c.232_233insA and 3 patients with a C233A mutation. Sixteen patients of the 59 patients subjected to the genetic analysis showed a mutation at the position -109 (1295213) in the TERT promoter region, the later mutation showed to be associated significantly with the grade of the reaction wheras the former mutation didn’t show that. On the other hand the two novel mutation showed a non-significant association with the levels of hTERT, age, gender, muscle invasiveness, recurrence and smoking and it was concluded from that the mutation in the TERT promoter region my have an effect on the TERT expression that participate in the bladder cancer pathogenisis which need further studies.
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2230-2238
The investigation of new mutations in telomerase reverse transcriptase promoter region in association with bladder cancer
Telomerase reverse transcriptase (TERT) is frequently reactivated in Urothelial Bladder Cancer (UBC) due to changes in its promoter region, rendering it a vital target for cancer-specific genetic modifications. The present work was aimed to investigate the TERT promoter region to explore the mutations that may affect the incidence and the pathogenesis of Urothelial Bladder Cancer in a study included 59 patients subjected to either transurethral bladder resection or radical cystectomy from which serum and tissue samples were obtained and the DNA extraction was performed with the use of purification Promega kit and the amplified DNA samples were sequenced by Sanger sequencing using an automated DNA sequencer to determine TERT gene promoter mutations. The results of the study showed that 47 patients out of 59 showed a mutation at the position -129 (1295233), 44 of them with c.232_233insA and 3 patients with a C233A mutation. Sixteen patients of the 59 patients subjected to the genetic analysis showed a mutation at the position -109 (1295213) in the TERT promoter region, the later mutation showed to be associated significantly with the grade of the reaction wheras the former mutation didn’t show that. On the other hand the two novel mutation showed a non-significant association with the levels of hTERT, age, gender, muscle invasiveness, recurrence and smoking and it was concluded from that the mutation in the TERT promoter region my have an effect on the TERT expression that participate in the bladder cancer pathogenisis which need further studies.
- Open Access
- 1 April 2025
- Published by University of Baghdad - Al-Kindy College of Medicine in AL-Kindy College Medical Journal
- Vol. 21 (1) , 11-16
Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
Background: Bladder cancer (BC) ranks as the tenth most common cancer globally, with a high recurrence rate. It is primarily caused by abnormalities in the epithelial layer lining the bladder and is classified from non-muscle invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). Fibroblast Growth Factor Receptor 3 (FGFR3) S249C mutation is frequently observed in low-grade NMIBC but are rare in high-grade NMIBC and MIBC, leading to continuous receptor activation and promoting tumor growth. Objective: This study aims to investigate the prevalence of FGFR3 S249C mutation in Iraqi BC patients, assess their association with tumor stage and grade, evaluate the potential of FGFR3 mutation as an early-stage diagnostic marker, and discuss implications for public health policy. Subjects and Methods: The study was conducted at Al-Safeer Hospital, Karbala, Iraq. It included 60 individuals diagnosed with urothelial BC (50 males, 83.3%; 10 females, 16.4%) with a median age of 63 years. Tumor tissue samples from patients undergoing Transurethral Resection of Bladder Tumor (TURBT) were used. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples, and FGFR3 mutations were examined through direct DNA sequencing, focusing on the S249C mutation in exon 7. The prevalence of the S249C mutation was analyzed in relation to tumor stage and grade. Results: The study revealed a significant prevalence (55%) of the S249C mutation. This mutation was more frequent among males and individuals over the age of 50 years. There was a higher incidence of BC in males (83.3%) compared to females (16.7%), especially in those aged 50 years and older. Histomorphological evaluations showed a considerable number of tumors classified as low-grade. Furthermore, pathological staging results identified pT1 as the most common stage, followed by pTa and pT2, underscoring the predominance of early-stage tumors within the study population. Conclusions: This study highlighted the significant prevalence of FGFR3 S249C mutation in Iraqi BC patients. FGFR3 mutations were strongly associated with early-stage and low-grade tumors, indicating their potential as a molecular marker for early diagnosis.
- 1 April 2025
- Published by University of Baghdad - Al-Kindy College of Medicine in AL-Kindy College Medical Journal
- Vol. 21 (1) , 11-16
Open AccessFibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
Background: Bladder cancer (BC) ranks as the tenth most common cancer globally, with a high recurrence rate. It is primarily caused by abnormalities in the epithelial layer lining the bladder and is classified from non-muscle invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). Fibroblast Growth Factor Receptor 3 (FGFR3) S249C mutation is frequently observed in low-grade NMIBC but are rare in high-grade NMIBC and MIBC, leading to continuous receptor activation and promoting tumor growth. Objective: This study aims to investigate the prevalence of FGFR3 S249C mutation in Iraqi BC patients, assess their association with tumor stage and grade, evaluate the potential of FGFR3 mutation as an early-stage diagnostic marker, and discuss implications for public health policy. Subjects and Methods: The study was conducted at Al-Safeer Hospital, Karbala, Iraq. It included 60 individuals diagnosed with urothelial BC (50 males, 83.3%; 10 females, 16.4%) with a median age of 63 years. Tumor tissue samples from patients undergoing Transurethral Resection of Bladder Tumor (TURBT) were used. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples, and FGFR3 mutations were examined through direct DNA sequencing, focusing on the S249C mutation in exon 7. The prevalence of the S249C mutation was analyzed in relation to tumor stage and grade. Results: The study revealed a significant prevalence (55%) of the S249C mutation. This mutation was more frequent among males and individuals over the age of 50 years. There was a higher incidence of BC in males (83.3%) compared to females (16.7%), especially in those aged 50 years and older. Histomorphological evaluations showed a considerable number of tumors classified as low-grade. Furthermore, pathological staging results identified pT1 as the most common stage, followed by pTa and pT2, underscoring the predominance of early-stage tumors within the study population. Conclusions: This study highlighted the significant prevalence of FGFR3 S249C mutation in Iraqi BC patients. FGFR3 mutations were strongly associated with early-stage and low-grade tumors, indicating their potential as a molecular marker for early diagnosis.
- 2 February 2024
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (4) , 529-538
Circulating miRNA-373 and Vascular Endothelial Growth Factor as Potential Biomarkers for Early Detection of Breast Cancer
Breast cancer is the leading cause of cancer-related mortality among women worldwide. MicroRNAs (miRNAs), short non-coding RNAs, have been implicated in cancer-related processes such as tumor development, metastasis, angiogenesis, and drug resistance. Circulating miRNA-373 demonstrates higher relative exosomal serum levels in breast cancer patients compared to healthy women, making it a potential non-invasive biomarker. Separately, vascular endothelial growth factor (VEGF) is crucial for angiogenesis, and is elevated in breast cancer. In this case–control study, we aimed to investigate the diagnostic accuracy of miRNA-373 and VEGF as biomarkers for early-stage breast cancer detection. Serum samples were collected from 120 participants, comprising 30 breast cancer patients, 30 benign breast tumor patients, and 60 healthy controls, over the period of April 2022 to January 2023. MiRNA-373 expression was analyzed by reverse transcription-quantitative PCR with GAPDH normalisation, while VEGF levels in serum samples were measured by ELISA. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of both biomarkers. MiRNA-373 expression (∆Ct) differed significantly between the three groups (breast cancer: − 12.20 ± 1.11; benign tumors: − 12.79 ± 1.09; controls: − 13.64 ± 0.93). ROC analysis revealed moderate discriminative power for miRNA-373 (specificity = 76.7%; sensitivity = 70.0%; AUC = 0.839) and excellent discriminative power for VEGF (specificity = 85.0%; sensitivity = 90.0%; AUC = 0.944) in distinguishing early-stage breast cancer patients from healthy controls. In summary, this study demonstrates the promising potential of miRNA-373 as an early diagnostic biomarker for breast cancer detection, requiring further validation in larger cohorts. Our findings also reinforce the diagnostic value of circulating VEGF levels for breast cancer screening.
- 2 February 2024
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (4) , 529-538
Circulating miRNA-373 and Vascular Endothelial Growth Factor as Potential Biomarkers for Early Detection of Breast Cancer
Breast cancer is the leading cause of cancer-related mortality among women worldwide. MicroRNAs (miRNAs), short non-coding RNAs, have been implicated in cancer-related processes such as tumor development, metastasis, angiogenesis, and drug resistance. Circulating miRNA-373 demonstrates higher relative exosomal serum levels in breast cancer patients compared to healthy women, making it a potential non-invasive biomarker. Separately, vascular endothelial growth factor (VEGF) is crucial for angiogenesis, and is elevated in breast cancer. In this case–control study, we aimed to investigate the diagnostic accuracy of miRNA-373 and VEGF as biomarkers for early-stage breast cancer detection. Serum samples were collected from 120 participants, comprising 30 breast cancer patients, 30 benign breast tumor patients, and 60 healthy controls, over the period of April 2022 to January 2023. MiRNA-373 expression was analyzed by reverse transcription-quantitative PCR with GAPDH normalisation, while VEGF levels in serum samples were measured by ELISA. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of both biomarkers. MiRNA-373 expression (∆Ct) differed significantly between the three groups (breast cancer: − 12.20 ± 1.11; benign tumors: − 12.79 ± 1.09; controls: − 13.64 ± 0.93). ROC analysis revealed moderate discriminative power for miRNA-373 (specificity = 76.7%; sensitivity = 70.0%; AUC = 0.839) and excellent discriminative power for VEGF (specificity = 85.0%; sensitivity = 90.0%; AUC = 0.944) in distinguishing early-stage breast cancer patients from healthy controls. In summary, this study demonstrates the promising potential of miRNA-373 as an early diagnostic biomarker for breast cancer detection, requiring further validation in larger cohorts. Our findings also reinforce the diagnostic value of circulating VEGF levels for breast cancer screening.
- Open Access
- 13 December 2023
- Published by Egyptian Knowledge Bank in Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology
- Vol. 15 (2) , 805-811
Assessment of Serum Protein Carbonyls and Glycemic Biomarkers in Patients with Type 2 Diabetic Proliferative Retinopathy
Purpose: A case-control study was conducted to evaluate the role of protencarponyls and glycemic biomarkers in type two diabetic patients with proliferative diabetic retinopathy (PDR).Materials and Methods: a case-control study includes a comparison between 3 groups, (40 healthy persons ) as a control compared with (40 type-2 diabetic patients without proliferative retinopathy) and (40 diabetic patients with proliferative retinopathy) serum PC were determined with ELISA while glycemic biomarkers FBS, HbA1c was determined by spectrophotometry method ( autoanlyser technique). Result: PC serum level and FBS, HbA1c statistically significantly increased among the study groups, the highest level in PDR patients when compared with control groups and T2M Patients without RP. Conclusion: Protein carbonyls are increased significantly in both T2DM without PDR and PDR patients compared with healthy people ( control ).FBS and HbA1c decreased significantly in both T2DM without PDR and PDR patients compared with healthy people ( control ).
- 13 December 2023
- Published by Egyptian Knowledge Bank in Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology
- Vol. 15 (2) , 805-811
Open AccessAssessment of Serum Protein Carbonyls and Glycemic Biomarkers in Patients with Type 2 Diabetic Proliferative Retinopathy
Purpose: A case-control study was conducted to evaluate the role of protencarponyls and glycemic biomarkers in type two diabetic patients with proliferative diabetic retinopathy (PDR).Materials and Methods: a case-control study includes a comparison between 3 groups, (40 healthy persons ) as a control compared with (40 type-2 diabetic patients without proliferative retinopathy) and (40 diabetic patients with proliferative retinopathy) serum PC were determined with ELISA while glycemic biomarkers FBS, HbA1c was determined by spectrophotometry method ( autoanlyser technique). Result: PC serum level and FBS, HbA1c statistically significantly increased among the study groups, the highest level in PDR patients when compared with control groups and T2M Patients without RP. Conclusion: Protein carbonyls are increased significantly in both T2DM without PDR and PDR patients compared with healthy people ( control ).FBS and HbA1c decreased significantly in both T2DM without PDR and PDR patients compared with healthy people ( control ).
- 20 June 2022
- Published by American Institute of Aeronautics and Astronautics (AIAA)
High-Order Implicit Shock Tracking for a Supersonic Biplane Airfoil
View Video Presentation: https://doi.org/10.2514/6.2022-4082.vid Implicit shock tracking is a class of numerical methods to approximate solutions of conservation laws with non-smooth features, e.g., contact lines, shock waves, and rarefactions. These methods align elements of the computational mesh with non-smooth features to represent them perfectly, allowing high-order basis functions to approximate smooth regions of the solution without the need for nonlinear stabilization, which leads to accurate approximations on traditionally coarse meshes. In this work, we use the High-Order Implicit Shock Tracking method to solve for steady, compressible flow over a Busemann-type biplane at different inflow Mach numbers. We identify challenges that arise when fitting shocks in different Mach regimes, and show targeted h-refinement can overcome these issues and lead to precise alignment of the grid with shocks, even beginning from an unstructured mesh with no knowledge of the shock structure.
- 20 June 2022
- Published by American Institute of Aeronautics and Astronautics (AIAA)
High-Order Implicit Shock Tracking for a Supersonic Biplane Airfoil
View Video Presentation: https://doi.org/10.2514/6.2022-4082.vid Implicit shock tracking is a class of numerical methods to approximate solutions of conservation laws with non-smooth features, e.g., contact lines, shock waves, and rarefactions. These methods align elements of the computational mesh with non-smooth features to represent them perfectly, allowing high-order basis functions to approximate smooth regions of the solution without the need for nonlinear stabilization, which leads to accurate approximations on traditionally coarse meshes. In this work, we use the High-Order Implicit Shock Tracking method to solve for steady, compressible flow over a Busemann-type biplane at different inflow Mach numbers. We identify challenges that arise when fitting shocks in different Mach regimes, and show targeted h-refinement can overcome these issues and lead to precise alignment of the grid with shocks, even beginning from an unstructured mesh with no knowledge of the shock structure.
- Open Access
- 7 April 2022
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 69 (2) , 309-314
Evaluation of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) and sLOX-1/oxidized LDL ratio as novel biomarkers of acute coronary syndrome
The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is involved in the pathophysiology of atherosclerosis and acute coronary syndromes (ACS). In patients with acute coronary syndrome, circulating soluble LOX-1 (sLOX-1) levels are dramatically elevated. This study aimed to assess sLOX-1 levels in acute coronary syndromes and determine the ratio of sLOX-1 and oxidative LDL in cases of myocardial infarction and unstable angina pectoris and the ROC curve for this ratio sLOX-1. A case-control study was conducted at the department of chemistry and biochemistry, college of medicine, Al- Nahrain University, Baghdad, Iraq, from September 2020 to January 2021. In a total of 90 subjects (30 patients with myocardial infarction within the first six hours of chest pains, 30 patients with unstable angina pectoris, and 30 healthy donors). The ELISA technique measured concentrations of sLOX-1 and oxidized LDL. In addition, Troponin and highly sensitive C reactive protein were measured by the same technique (Fluorescence immune assay), and lipid profile was measured using the Spectrophotometer technique. The median level of sLOX-1 in MI group was 476.17 pg/ml (90.88–675.4 pg/ml) which was significantly higher than that of UA patients (median=289.1 pg/ml [62.74-585.43 pg/ml]) and controls (median=144.52 pg/ml [79.17-283.83 pg/ml]) with highly significant differences and the median sLOX-1/OX-LDL ratio in patients with MI was 64.6 (range 15.17-100.15) which was significantly higher than either patients with UA (median=37.6 [7.06-88.65]) or controls (median=25.29 [12.7-43.04]). There were elevated levels of sLOX-1 in acute coronary syndromes. The sLOX-1/oxidized LDL ratio also strongly indicated the diagnosis and a discriminatory force on the ROC curve for myocardial infarction.
- 7 April 2022
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 69 (2) , 309-314
Open AccessEvaluation of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) and sLOX-1/oxidized LDL ratio as novel biomarkers of acute coronary syndrome
The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is involved in the pathophysiology of atherosclerosis and acute coronary syndromes (ACS). In patients with acute coronary syndrome, circulating soluble LOX-1 (sLOX-1) levels are dramatically elevated. This study aimed to assess sLOX-1 levels in acute coronary syndromes and determine the ratio of sLOX-1 and oxidative LDL in cases of myocardial infarction and unstable angina pectoris and the ROC curve for this ratio sLOX-1. A case-control study was conducted at the department of chemistry and biochemistry, college of medicine, Al- Nahrain University, Baghdad, Iraq, from September 2020 to January 2021. In a total of 90 subjects (30 patients with myocardial infarction within the first six hours of chest pains, 30 patients with unstable angina pectoris, and 30 healthy donors). The ELISA technique measured concentrations of sLOX-1 and oxidized LDL. In addition, Troponin and highly sensitive C reactive protein were measured by the same technique (Fluorescence immune assay), and lipid profile was measured using the Spectrophotometer technique. The median level of sLOX-1 in MI group was 476.17 pg/ml (90.88–675.4 pg/ml) which was significantly higher than that of UA patients (median=289.1 pg/ml [62.74-585.43 pg/ml]) and controls (median=144.52 pg/ml [79.17-283.83 pg/ml]) with highly significant differences and the median sLOX-1/OX-LDL ratio in patients with MI was 64.6 (range 15.17-100.15) which was significantly higher than either patients with UA (median=37.6 [7.06-88.65]) or controls (median=25.29 [12.7-43.04]). There were elevated levels of sLOX-1 in acute coronary syndromes. The sLOX-1/oxidized LDL ratio also strongly indicated the diagnosis and a discriminatory force on the ROC curve for myocardial infarction.
- Open Access
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (B) , 321-325
The Impact of Different rs3917538 Genotypes with the PON-1 Activity, Atherosclerosis Severity in Patients of Coronary Atherosclerosis
Background: Coronary atherosclerosis is one of the coronary artery diseases (CAD) responsible for a significant percentage of mortality and morbidity in Iraqi subjects. Atherosclerosis compresses about 17 million death cases; 45% are under the age of 70. The improvement in atherosclerosis disease management paly a critical role in preventing this disease; despite that, new risk factors have been studied, including genetic studies. Many polymorphisms have been associated with coronary atherosclerosis in different ethnic populations. Paraoxonase is an enzyme located on HDL in serum. PON acts as a protective factor or agent against oxidative modification of LDL, suggesting that it could play an essential and influential role in atherosclerotic processes prevention. Objective: To evaluate the rs3917538 genotypes in the PON-1 gene associated with the coronary atherosclerosis risk and the effect of this single nucleotide polymorphism on the serum activity of PON-1 and the severity of coronary atherosclerosis. Methods: A case-control study included sixty patients diagnosed with coronary atherosclerosis and sixty healthy volunteers diagnosed with angiography examination. The study was carried out during the period from February 2019 till June 2020. Serum PON-1 was measured by fluorometric technique, and the genetic assessment was by RT-PCR technique. Results: The activity for PON-1 in patients was significantly lower than controls; the median activity of PON-1 in controls was 197.32 mU/ml, which was higher than that of patients (median =163.46 mU/ml). There was an impact of rs3917538 genotypes on the severity of the disease, P=0.041. The rs3917538 genotypes have no association with the risk of coronary atherosclerosis and the activity of PON-1. Conclusion: The measurement of serum PON-1 activity may help in the diagnosis of coronary atherosclerosis patients. The rs3917538 genotypes in the PON-1 gene among the patient’s group impact the severity of coronary atherosclerosis.
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (B) , 321-325
Open AccessThe Impact of Different rs3917538 Genotypes with the PON-1 Activity, Atherosclerosis Severity in Patients of Coronary Atherosclerosis
Background: Coronary atherosclerosis is one of the coronary artery diseases (CAD) responsible for a significant percentage of mortality and morbidity in Iraqi subjects. Atherosclerosis compresses about 17 million death cases; 45% are under the age of 70. The improvement in atherosclerosis disease management paly a critical role in preventing this disease; despite that, new risk factors have been studied, including genetic studies. Many polymorphisms have been associated with coronary atherosclerosis in different ethnic populations. Paraoxonase is an enzyme located on HDL in serum. PON acts as a protective factor or agent against oxidative modification of LDL, suggesting that it could play an essential and influential role in atherosclerotic processes prevention. Objective: To evaluate the rs3917538 genotypes in the PON-1 gene associated with the coronary atherosclerosis risk and the effect of this single nucleotide polymorphism on the serum activity of PON-1 and the severity of coronary atherosclerosis. Methods: A case-control study included sixty patients diagnosed with coronary atherosclerosis and sixty healthy volunteers diagnosed with angiography examination. The study was carried out during the period from February 2019 till June 2020. Serum PON-1 was measured by fluorometric technique, and the genetic assessment was by RT-PCR technique. Results: The activity for PON-1 in patients was significantly lower than controls; the median activity of PON-1 in controls was 197.32 mU/ml, which was higher than that of patients (median =163.46 mU/ml). There was an impact of rs3917538 genotypes on the severity of the disease, P=0.041. The rs3917538 genotypes have no association with the risk of coronary atherosclerosis and the activity of PON-1. Conclusion: The measurement of serum PON-1 activity may help in the diagnosis of coronary atherosclerosis patients. The rs3917538 genotypes in the PON-1 gene among the patient’s group impact the severity of coronary atherosclerosis.
- Open Access
- 10 January 2021
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 9 (A) , 894-900
The Impact of Luteinizing Hormone/Chorionic Gonadotropin Hormone Receptor Gene Polymorphism rs68073206 in Men with Non-obstructive Azoospermia: A Case-control Study
Background: The functional consequences of the luteinizing hormone/chorionic gonadotropin hormone receptor (LHCGR) gene single nucleotide polymorphism (rs68073206) on male infertility in patients with non-obstructive azoospermia (NOA) is not clear. Objective: To examine whether the presence of LHCGR gene; rs68073206 single nucleotide polymorphisms (SNPs) can be associated with incidence of non-obstructive azoospermia. Materials and methods: A case-control study comprised of a total of 70 unrelated Iraqi infertile men with non-obstructive azoospermia (zero sperm in semen) whose were on two groups: Group I that were diagnosed to have NOA but didn’t receive infertility treatment yet (33 patient with age of 31.58±1.059 year) and group II that were receiving injectable gonadotropin treatment (37 patient with age of 33.46±1.173 year). In addition to 34 age and BMI matched healthy fertile normozoospermic men (according to the parameters of WHO, 2010). The study population was genotyped by TaqMan assay for LHCGR gene single nucleotide polymorphism (rs68073206). The level of each hormone was estimated by immunoassay technique while the sperm analyses were conducted in accordance with the World Health Organization criteria. Results: The study revealed a statistically significant higher hormonal level of serum inhibin B in infertile group I patients with wild GG genotype (246.445±224.106 pg/ml), and the p-value is (0.0439) as compared to that hormone levels of GT and TT genotypes carriers that were (85.969±71.685 pg/ml) and (56.420±23.988 pg/ml) respectively. ). The genotyping variations of patients, whether carrying the homozygous GG, heterozygous GT or homozygous TT genotype, did not reveal a statistically significant difference in distribution as compared to control individuals. Conclusions: The LHCGR gene rs68073206 polymorphisms in our population having non-obstructive azoospermia can be suggested to have a modulating potential in variable gonadotropin sensitivity. The detected non-significant difference in genotypic prevalence can be attributable to the limited sample size.
- 10 January 2021
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 9 (A) , 894-900
Open AccessThe Impact of Luteinizing Hormone/Chorionic Gonadotropin Hormone Receptor Gene Polymorphism rs68073206 in Men with Non-obstructive Azoospermia: A Case-control Study
Background: The functional consequences of the luteinizing hormone/chorionic gonadotropin hormone receptor (LHCGR) gene single nucleotide polymorphism (rs68073206) on male infertility in patients with non-obstructive azoospermia (NOA) is not clear. Objective: To examine whether the presence of LHCGR gene; rs68073206 single nucleotide polymorphisms (SNPs) can be associated with incidence of non-obstructive azoospermia. Materials and methods: A case-control study comprised of a total of 70 unrelated Iraqi infertile men with non-obstructive azoospermia (zero sperm in semen) whose were on two groups: Group I that were diagnosed to have NOA but didn’t receive infertility treatment yet (33 patient with age of 31.58±1.059 year) and group II that were receiving injectable gonadotropin treatment (37 patient with age of 33.46±1.173 year). In addition to 34 age and BMI matched healthy fertile normozoospermic men (according to the parameters of WHO, 2010). The study population was genotyped by TaqMan assay for LHCGR gene single nucleotide polymorphism (rs68073206). The level of each hormone was estimated by immunoassay technique while the sperm analyses were conducted in accordance with the World Health Organization criteria. Results: The study revealed a statistically significant higher hormonal level of serum inhibin B in infertile group I patients with wild GG genotype (246.445±224.106 pg/ml), and the p-value is (0.0439) as compared to that hormone levels of GT and TT genotypes carriers that were (85.969±71.685 pg/ml) and (56.420±23.988 pg/ml) respectively. ). The genotyping variations of patients, whether carrying the homozygous GG, heterozygous GT or homozygous TT genotype, did not reveal a statistically significant difference in distribution as compared to control individuals. Conclusions: The LHCGR gene rs68073206 polymorphisms in our population having non-obstructive azoospermia can be suggested to have a modulating potential in variable gonadotropin sensitivity. The detected non-significant difference in genotypic prevalence can be attributable to the limited sample size.
- Open Access
- 26 December 2020
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 9 (B) , 1462-1469
The Evaluation of Methylated Septin 9 in Blood Plasma and Tissue Biopsies for the Early Detection for Asymptomatic Colon Cancer
The purpose of this study was to assess the utility of the SEPT9 genetic marker in the early detection of colon cancer patients. A case-control study was conducted on forty newly diagnosed colon cancer patients. The study was done between March 2019 and January 2020, patients from the Gastroenterology and Liver Education Hospital, Al-imamain Al-Kadhimain Medical City, and Baghdad Teaching Hospital were recruited. Colon cancer patients' mean age ± standard deviation was 54.4 ± 10.79 years while the age ± standard deviation of the mean of the control group was 55.1±8.54 years. For septin9 tissue methylation of the controls was done on the non-malignant tissues of the same patients. This study concluded that the percentage of Septin 9 (SEPT9) in the tissue of patients with colon cancer (CC) was the highest value, which is more significant than that of the serum of CC patients. Both of these groups were significantly higher than the percentage of SEPT9 methylation of control tissue and serum. Non-significant differences were obtained in the levels of CEA and CA19-9 between CC patients and controls.
- 26 December 2020
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 9 (B) , 1462-1469
Open AccessThe Evaluation of Methylated Septin 9 in Blood Plasma and Tissue Biopsies for the Early Detection for Asymptomatic Colon Cancer
The purpose of this study was to assess the utility of the SEPT9 genetic marker in the early detection of colon cancer patients. A case-control study was conducted on forty newly diagnosed colon cancer patients. The study was done between March 2019 and January 2020, patients from the Gastroenterology and Liver Education Hospital, Al-imamain Al-Kadhimain Medical City, and Baghdad Teaching Hospital were recruited. Colon cancer patients' mean age ± standard deviation was 54.4 ± 10.79 years while the age ± standard deviation of the mean of the control group was 55.1±8.54 years. For septin9 tissue methylation of the controls was done on the non-malignant tissues of the same patients. This study concluded that the percentage of Septin 9 (SEPT9) in the tissue of patients with colon cancer (CC) was the highest value, which is more significant than that of the serum of CC patients. Both of these groups were significantly higher than the percentage of SEPT9 methylation of control tissue and serum. Non-significant differences were obtained in the levels of CEA and CA19-9 between CC patients and controls.
- Open Access
- 3 April 2020
- Published by GP Innovations Pvt. Ltd. in International Journal of Research in Pharmaceutical Sciences
- Vol. 11 (2) , 1438-1446
The role of Ghrelin Receptor Expression in the Diagnosis of breast cancer
To determine the possible role of the assessment of Ghrelin receptor expression in breast tissues as a tool for the diagnosis of breast cancer and differentiate it from a benign breast tumor. A case-control study was done on 60 female patients with breast cancer and 60 female patients with benign breast tumors (Fibroadenoma) who were recruited from Al Imamain Al-Kadhemain Medical City and Oncology teaching Hospital, Baghdad, Iraq between May 2018 and December 2018. Immunohistochemical staining was done on the breast tissue samples obtained from patients and compared with the control group, which comprised 75 fibrocystic tissue samples obtained from age, BMI and sex-matched females. The degree of Ghrelin Receptor expression was determined immunohistochemically. The expression of Ghrelin receptors in breast malignant tumor tissues was higher than that in benign breast tumor tissues and controls, in addition to that, results obtained from all groups revealed that Ghrelin receptor intensity and its expression proportion were strongly and significantly associated with the type of tissues. The expression of the Ghrelin receptor can be considered as a highly significant immunohistochemical marker for the detection of breast tumors and for the differentiation between both types of tumors; benign and malignant.
- 3 April 2020
- Published by GP Innovations Pvt. Ltd. in International Journal of Research in Pharmaceutical Sciences
- Vol. 11 (2) , 1438-1446
Open AccessThe role of Ghrelin Receptor Expression in the Diagnosis of breast cancer
To determine the possible role of the assessment of Ghrelin receptor expression in breast tissues as a tool for the diagnosis of breast cancer and differentiate it from a benign breast tumor. A case-control study was done on 60 female patients with breast cancer and 60 female patients with benign breast tumors (Fibroadenoma) who were recruited from Al Imamain Al-Kadhemain Medical City and Oncology teaching Hospital, Baghdad, Iraq between May 2018 and December 2018. Immunohistochemical staining was done on the breast tissue samples obtained from patients and compared with the control group, which comprised 75 fibrocystic tissue samples obtained from age, BMI and sex-matched females. The degree of Ghrelin Receptor expression was determined immunohistochemically. The expression of Ghrelin receptors in breast malignant tumor tissues was higher than that in benign breast tumor tissues and controls, in addition to that, results obtained from all groups revealed that Ghrelin receptor intensity and its expression proportion were strongly and significantly associated with the type of tissues. The expression of the Ghrelin receptor can be considered as a highly significant immunohistochemical marker for the detection of breast tumors and for the differentiation between both types of tumors; benign and malignant.